iTeos Therapeutics, Inc. (NASDAQ: ITOS) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT ITEOS THERAPEUTICS, INC.

iTeos Therapeutics, Inc. (NASDAQ: ITOS)
Listen to this Section


$7.82
+0.3400 ( +4.27% ) 112.3K

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Market Data


Open $7.82
Previous Close $7.48
Volume 112.3K
Market Cap $274.74M
Day Range $7.48 - $7.90
52 Week Range $7.09 - $18.75
Shares Outstanding 36.53M
Change % +4.27%
Net Change ▲ 0.3400
Insider Ownership -0.08%
Exchange NASDAQ
Sector Miscellaneous
Industry None
IPO Year 2020
Country United States
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -2,621,835.00

Date Type Amount Purchased Purchaser
2024-11-19 Buy 5000.00 Gall Matthew
2024-08-09 Sale -442800.00 Detheux Michel
2024-08-05 Sale -350000.00 Feltquate David
2024-06-13 Sale -24200.00 Van Hauwermeiren Timothy
2024-06-13 Sale -24200.00 Lee David K
2024-06-13 Sale -24200.00 Davis Aaron I.
2024-06-13 Sale -24200.00 Hallal David
2024-06-13 Sale -24200.00 RHOADS ANN D
2024-06-13 Sale -24200.00 Iannone Robert
2024-06-13 Sale -24200.00 DeSimone Jill

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Dec 06, 2024
4 Insider transactions 1 Nov 19, 2024
10-q Quarterly Reports 68 Nov 12, 2024
8-k 8K-related 11 Nov 04, 2024
8-k 8K-related 34 Sep 16, 2024
4 Insider transactions 1 Aug 09, 2024
10-q Quarterly Reports 70 Aug 08, 2024
4 Insider transactions 1 Aug 05, 2024
3 Insider transactions 2 Aug 05, 2024
4 Insider transactions 1 Jun 13, 2024

Latest News


× Before browsing our site, please accept our cookies policy